Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics.

Abstract

AIM:

The occurrence of metabolic syndrome (MS) in schizophrenia patients receiving long-term antipsychotics (APs) contributes to their high mortality rate. We aimed to determine whether genetic polymorphisms of identified candidate genes are associated with MS in our study population.

MATERIALS & METHODS:

We recruited 206 schizophrenia patients receiving AP treatment for at least a year. Cross-sectional measurements of weight, height, blood pressure, waist and hip circumference, and other lipid profiles were recorded. Patient DNA was genotyped for 16 candidate gene polymorphisms.

RESULTS:

Of these patients, 59.7% were found to have MS while 40.3% did not. All metabolic parameters were significantly different between the two groups. Only three of the 16 polymorphisms studied showed significant association with MS; rs9939609 of the FTO gene confers risk for MS (odds ratio [OR]: 1.73, 95% CI: 1.07-2.78, p = 0.026), while rs1137101 of the LEPR gene (OR: 0.47, 95% CI: 0.28-0.80, p = 0.005) and rs1801133 of the MTHFR gene (OR: 0.59, 95% CI: 0.35-0.99, p = 0.049) are protective against MS.

CONCLUSION:

Polymorphisms of the FTO, LEPR and MTHFR genes may play a role in MS in Malaysian schizophrenia patients receiving long-term treatment with APs.

• Authors: Siti Norsyuhada Roffeei, Zahurin Mohamed, Gavin P Reynolds, Mas Ayu Said, Ahmad Hatim, Elsa Haniffah Mejia Mohamed, Syarinaz Ahmad Aida, Nor Zuraida Zainal
• Journal: Pharmacogenomics (Pharmacogenomics) Vol. 15 Issue 4 Pg. 477-85 (Mar 2014) ISSN: 1744-8042 [Electronic] England
• PMID: 24624915 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antipsychotic Agents
• LEPR protein, human
• Proteins
• Receptors, Leptin
• Alpha-Ketoglutarate-Dependent Dioxygenase FTO
• FTO protein, human
• MTHFR protein, human
• Methylenetetrahydrofolate Reductase (NADPH2)

Topics

• Adult
• Alpha-Ketoglutarate-Dependent Dioxygenase FTO
• Antipsychotic Agents (adverse effects, therapeutic use)
• Cross-Sectional Studies
• Female
• Genotype
• Humans
• Male
• Metabolic Syndrome (chemically induced, genetics)
• Methylenetetrahydrofolate Reductase (NADPH2) (genetics)
• Polymorphism, Single Nucleotide (genetics)
• Proteins (genetics)
• Receptors, Leptin (genetics)
• Risk
• Schizophrenia (drug therapy, genetics)